Targeted extracellular vesicle delivery systems employing superparamagnetic iron oxide nanoparticles

Zhuo, Zewei; Wang, Jinghua; Luo, Yujun; Zeng, Ruijie; Zhang, Chen; Zhou, Weijie; Guo, Kehang; Wu, Huihuan; Sha, Weihong; Chen, Hao

doi:10.1016/j.actbio.2021.07.027

Cited by 49 publications

(45 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A huge body of literature clearly indicates broad applications of aptamers ranging from imaging to clinical diagnostics, cytokine detection, detection of small molecules and much more [5,7,47,48]. Moreover, in recent years utility of aptamers has also been demonstrated to detect EVs from cancer cells by capturing the cells through aptamers targeting CD63, EpCAM, PDGF-β receptor or nucleolin [49][50][51].…”

Section: Discussionmentioning

confidence: 99%

Development of DNA Aptamers to Visualize Release of Mycobacterial Membrane-Derived Extracellular Vesicles in Infected Macrophages

et al. 2021

View full text Add to dashboard Cite

Extracellular vesicles (EVs) have emerged into a novel vaccine platform, a biomarker and a nano-carrier for approved drugs. Their accurate detection and visualization are central to their utility in varied biomedical fields. Owing to the limitations of fluorescent dyes and antibodies, here, we describe DNA aptamer as a promising tool for visualizing mycobacterial EVs in vitro. Employing SELEX from a large DNA aptamer library, we identified a best-performing aptamer that is highly specific and binds at nanomolar affinity to EVs derived from three diverse mycobacterial strains (pathogenic, attenuated and avirulent). Confocal microscopy revealed that this aptamer was not only bound to in vitro-enriched mycobacterial EVs but also detected EVs that were internalized by THP-1 macrophages and released by infecting mycobacteria. To the best of our knowledge, this is the first study that detects EVs released by mycobacteria during infection in host macrophages. Within 4 h, most released mycobacterial EVs spread to other parts of the host cell. We predict that this tool will soon hold huge potential in not only delineating mycobacterial EVs-driven pathogenic functions but also in harboring immense propensity to act as a non-invasive diagnostic tool against tuberculosis in general, and extra-pulmonary tuberculosis in particular.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of DNA Aptamers to Visualize Release of Mycobacterial Membrane-Derived Extracellular Vesicles in Infected Macrophages

et al. 2021

View full text Add to dashboard Cite

show abstract

“…have designed magnetic and targeting EVs as a targeted drug delivery vehicle for hepatoma cancer therapy. Superparamagnetic iron oxide nanoparticles are one of the most commonly used nanomaterials for targeted modification of EVs (Zhuo et al., 2021 ). Multiple superparamagnetic nanoparticles are anchored to the surface of blood-derived EVs through transferrin (Tf)-Tf receptor interaction (Qi et al., 2016 ).…”

Section: Delivery Of Nanomaterialsmentioning

confidence: 99%

Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy

et al. 2022

View full text Add to dashboard Cite

Increasing evidences show that unmodified extracellular vesicles (EVs) derived from various cells can effectively inhibit the malignant progression of different types of tumors by delivering the bioactive molecules. Therefore, EVs are expected to be developed as emerging anticancer drugs. Meanwhile, unmodified EVs as an advanced and promising nanocarrier that is frequently used in targeted delivery therapeutic cargos and personalized reagents for the treatment and diagnosis of cancer. To improve the efficacy of EV-based treatments, researchers are trying to engineering EVs as an emerging nanomedicine translational therapy platform through biological, physical and chemical approaches, which can be broaden and altered to enhance their therapeutic capability. EVs loaded with therapeutic components such as tumor suppressor drugs, siRNAs, proteins, peptides, and conjugates exhibit significantly enhanced anti-tumor effects. Moreover, the design and preparation of tumor-targeted modified EVs greatly enhance the specificity and effectiveness of tumor therapy, and these strategies are expected to become novel ideas for tumor precision medicine. This review will focus on reviewing the latest research progress of functionalized EVs, clarifying the superior biological functions and powerful therapeutic potential of EVs, for researchers to explore new design concepts based on EVs and build next-generation nanomedicine therapeutic platforms.

show abstract

“…Exosomes have been used as carriers loaded with microRNA [ 99 ], siRNA [ 100 ] and drugs, such as DOX [ 101 ], for glioma therapy. Exosome delivery systems also can carry SPIO for tumour MRI [ 102 ]. Exosomes have been used as MRI contrast agents for both imaging and the treatment of gliomas.…”

Section: Modification Of Mri Contrast Agentsmentioning

confidence: 99%

Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics

Dai

Tang

et al. 2021

Regenerative Biomaterials

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive malignant brain tumour, with a median survival of 3 months without treatment and 15 months with treatment. Early GBM diagnosis can significantly improve patient survival due to early treatment and management procedures. Magnetic resonance imaging (MRI) using contrast agents is the preferred method for the preoperative detection of GBM tumours. However, commercially available clinical contrast agents do not accurately distinguish between GBM, surrounding normal tissue and other cancer types due to their limited ability to cross the blood–brain barrier, their low relaxivity and their potential toxicity. New GBM-specific contrast agents are urgently needed to overcome the limitations of current contrast agents. Recent advances in nanotechnology have produced alternative GBM-targeting contrast agents. The surfaces of nanoparticles (NPs) can be modified with multimodal contrast imaging agents and ligands that can specifically enhance the accumulation of NPs at GBM sites. Using advanced imaging technology, multimodal NP-based contrast agents have been used to obtain accurate GBM diagnoses in addition to an increased amount of clinical diagnostic information. NPs can also serve as drug delivery systems for GBM treatments. This review focuses on the research progress for GBM-targeting MRI contrast agents as well as MRI-guided GBM therapy.

show abstract

Targeted extracellular vesicle delivery systems employing superparamagnetic iron oxide nanoparticles

Cited by 49 publications

References 187 publications

Development of DNA Aptamers to Visualize Release of Mycobacterial Membrane-Derived Extracellular Vesicles in Infected Macrophages

Development of DNA Aptamers to Visualize Release of Mycobacterial Membrane-Derived Extracellular Vesicles in Infected Macrophages

Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy

Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics

Contact Info

Product

Resources

About